Nebenwirkungen · Bimervax
BIMERVAX LP.8.1 emulsion for injection BIMERVAX LP.8.1 emulsion for injection in pre-filled syringe COVID-19 Vaccine (recombinant, adjuvanted) · Abschnitt 4.8 · PDF-Seite 34
HOS-151281 · Präparat HOS-100493
The safety of an additional booster dose of BIMERVAX as a fourth dose was assessed in 288 individuals, 18 years of age and older, who had completed either 3 doses of COVID-19 mRNA vaccine (tozinameran) or 2 doses of COVID-19 mRNA vaccine (tozinameran) and 1 dose of BIMERVAX, and received an additional booster dose with BIMERVAX between 6 and 12 months after the third previous dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T13:15:05Z · SHA-256 9021815ee653b04aa62b8ee1b9ae8cc9cdf72bb8edc2998f5a88fe9d974331b9 · Passage ea7900312161079651e80fb44f2a2dbf92d29d38bbed771c1502fb045075e621 · Zeichen 2806–3190 im Abschnitt